A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
PaxVax, Inc.
ClinicalTrials.gov Identifier:
NCT01979406
First received: October 16, 2013
Last updated: July 25, 2014
Last verified: July 2014
  Purpose

The purpose of this study is to evaluate 2 vaccine candidates against anthrax compared to the positive (vaccine) control as studied in normal healthy volunteers.


Condition Intervention Phase
Anthrax Infection
Biological: AVA
Biological: Ad4-PA-1
Biological: Ad4-PA-GPI-1
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 1 Randomized Double-Blind Positive-Controlled Ascending Dose Study to Evaluate the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4 Anthrax Vector Candidate Vaccines - Ad4-PA (Protective Antigen)and Ad4-PA-GPI (Glycosylphosphatidylinositol)

Resource links provided by NLM:


Further study details as provided by PaxVax, Inc.:

Primary Outcome Measures:
  • The safety, tolerability and immunogenicity of the Ad4 PA and Ad4 PA GPI vaccines across a range of dosages and schedules. [ Time Frame: Day 1 through Day 211 ] [ Designated as safety issue: No ]
    Safety will be measured by looking at safety labs, Adverse Events (AEs) and vaccine reactogenicity data from Baseline through Day 211. Immunogenicity will be measured by the peak serum antibody response to the PA transgene defined as the highest toxin-neutralizing antibody (TNA) titer achieved by a subject at any time between the first post-vaccination visit though Day 85 (and Day 211 if Day 85 is positive).


Secondary Outcome Measures:
  • Antibody response of the Ad4-PA formulation to Ad4 PA GPI [ Time Frame: Day 1 through Day 85 (Day 211 if Day 85 is positive) ] [ Designated as safety issue: No ]
    Antibody response will be tested via enzyme-linked immunosorbent assay (ELISA) and the peak PA-ELISA titer defined as the highest ELISA titer achieved by a subject at any time between the first post-vaccination visit and Day 85

  • Antibody response of the Ad4-PA and Ad4-PA-GPI vaccination regimens to the anticipated AVA PEP regimen. [ Time Frame: Days 1 through 85 (Day 211 if Day 85 is positive) ] [ Designated as safety issue: No ]
    Antibody response will be tested via ELISA and the peak PA-ELISA titer defined as the highest ELISA titer achieved by a subject at any time between the first post-vaccination visit and Day 85.

  • Antibody response induced by 3 different dosages of Ad4 PA and Ad4 PA GPI. [ Time Frame: Days 1 through 85 (Day 211 if Day 85 is positive) ] [ Designated as safety issue: No ]
    Antibody response will be tested via ELISA and the peak PA-ELISA titer defined as the highest ELISA titer achieved by a subject at any time between the first post-vaccination visit and Day 85 and titers will be compared across the 3 different dosages of Ad4 PA and Ad4 PA GPI (10^9, 10^10, 10^11).

  • TNA and antibody response induced by Ad4 PA and Ad4 PA GPI on 3 different vaccination schedules. [ Time Frame: Days 1 through 85 (Day 211 if Day 85 is positive) ] [ Designated as safety issue: No ]

    Antibody response will be tested via ELISA and the peak PA-ELISA titer defined as the highest ELISA titer achieved by a subject at any time between the first post-vaccination visit and Day 85, and compared among 3 vaccine schedules:

    1. Day 1: Ad4-PA or Ad4-PA-GPI, Day 15 placebo Day 29 AVA boost;
    2. Day 1:Ad4-PA or Ad4-PA-GPI, Day 15 AVA boost + Placebo; and
    3. Days 1, 15 and 29: Ad4-PA or Ad4-PA-GPI

  • Pre-existing Ad4 immunity on TNA and PA-ELISA response induced by Ad4 PA and Ad4 PA GPI. [ Time Frame: Days 1 through 85 (Day 211 if Day 85 is positive) ] [ Designated as safety issue: No ]
    Antibody response will be tested via ELISA and the impact of pre-existing Ad4 serostatus (positive/negative) on TNA and PA-ELISA will be evaluated

  • Evaluate the kinetics of the TNA and PA-ELISA antibody response induced by 3 different doses of Ad4 PA and Ad4 PA GPI on 3 different administration schedules. [ Time Frame: Days 1 through 85 (Day 211 if Day 85 is positive) ] [ Designated as safety issue: No ]
    TNA and PA-ELISA titer at each post-vaccination visit as measured by ELISA will be compared across each dose group (10^9, 10^10 and 10^11 vp) and dosing schedule. In addition, the time to peak pre-boost TNA titer and to peak pre-boost PA-ELISA titer will be compared across each dose group and dosing schedule. Cumulative TNA and PA-ELISA seroconversion through each post-vaccination visit and through Day 85

  • In vivo replication/excretion of the Ad4 PA and Ad4 PA GPI vaccines [ Time Frame: Days 1 through 211 ] [ Designated as safety issue: No ]
    The duration of in vivo replication/excretion will be measured by the Ad4 MN seroconversion and titer measured via ELISA testing. Vaccine take defined as either Ad4 micro-neutralizing (MN) seroconversion and/or detection of vaccine shedding measured by polymerase chain reaction (PCR) and confirmed by culture at any time point from Day 1 through Day 211


Other Outcome Measures:
  • Systemic PA-specific cellular immune response induced by Ad4-PA and Ad4-PA-GPI [ Time Frame: Days 1 through 43 ] [ Designated as safety issue: No ]
    The systemic PA-specific cellular immune response induced by Ad4-PA and Ad4-PA-GPI will be measured via cell-based assay on peripheral blood mononuclear cells(PBMCs). The tests will be performed on Days 1, 15, 29 and 43.

  • Mucosal PA-ELISA antibody responses induced by Ad4-PA and Ad4 PA-GPI [ Time Frame: Days 1 through 29 ] [ Designated as safety issue: No ]
    PA antibody titers from mucosal samples will be obtained on Days 1 and 29 and titers will be compared among the 2 vaccine candidates.


Estimated Enrollment: 120
Study Start Date: October 2013
Estimated Study Completion Date: February 2015
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: AVA
Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
Biological: AVA
Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
Other Name: Anthrax vaccine adsorbed (BioThrax)
Experimental: Ad4-PA-1

Given at 10^9, 10^10 and 10^11 vp

Ad4-PA at Day 1 + oral placebo on Day 15 + AVA boost at Day 29

Biological: AVA
Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
Other Name: Anthrax vaccine adsorbed (BioThrax)
Biological: Ad4-PA-1
Ad4-PA will be given at 10^9, 10^10 and 10^11 on Day, followed by an oral placebo on Day 15 and an AVA boost on Day 29
Other Name: Adenovirus serotype 4 vector vaccine against anthrax PA
Experimental: Ad4-PA-2

Given at 10^9, 10^10 and 10^11 vp

Ad4-PA at Days 1, 15 and 29

Biological: Ad4-PA-1
Ad4-PA will be given at 10^9, 10^10 and 10^11 on Day, followed by an oral placebo on Day 15 and an AVA boost on Day 29
Other Name: Adenovirus serotype 4 vector vaccine against anthrax PA
Experimental: Ad4-PA-3

Ad4 given at 10^9, 10^10 and 10^11 vp

Ad4 PA-GPI at Day 1 + AVA boost at Day 15 + placebo on Day 29

Biological: AVA
Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
Other Name: Anthrax vaccine adsorbed (BioThrax)
Biological: Ad4-PA-1
Ad4-PA will be given at 10^9, 10^10 and 10^11 on Day, followed by an oral placebo on Day 15 and an AVA boost on Day 29
Other Name: Adenovirus serotype 4 vector vaccine against anthrax PA
Experimental: Ad4-PA-GPI-1

Given at 10^9, 10^10 and 10^11 viral particles

Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15

Biological: AVA
Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
Other Name: Anthrax vaccine adsorbed (BioThrax)
Biological: Ad4-PA-GPI-1

Given at 10^9, 10^10 and 10^11 viral particles

Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15

Other Name: Adenovirus anthrax vaccine serotype 4 against anthrax PA
Experimental: Ad4 PA-GPI-2

Given at 10^9, 10^10 and 10^11 viral particles

Ad4 PA-GPI at Day 1 + placebo on Day 15 + AVA boost at Day 29

Biological: AVA
Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
Other Name: Anthrax vaccine adsorbed (BioThrax)
Biological: Ad4-PA-GPI-1

Given at 10^9, 10^10 and 10^11 viral particles

Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15

Other Name: Adenovirus anthrax vaccine serotype 4 against anthrax PA
Experimental: Ad4-PA-GPI -3

Given at 10^9, 10^10 and 10^11 viral particles

Ad4-PA-GPI at Days 1, 15 and 29

Biological: Ad4-PA-GPI-1

Given at 10^9, 10^10 and 10^11 viral particles

Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15

Other Name: Adenovirus anthrax vaccine serotype 4 against anthrax PA

Detailed Description:

A Phase 1, randomized, double-blind, positive controlled, increasing dose clinical trial in healthy adult subjects at multiple sites. The study will assess safety and immunogenicity of two adenovirus vaccine candidates against anthrax compared to the positive control, Anthrax Vaccine Adsorbed (AVA). The trial will enroll 108 subjects in the anthrax vector vaccine arms and 12 subjects in the AVA positive control subjects. The study will look at three different dose of oral dosages of Ad4-PA (protective antigen) and Ad4-PA-GPI (10^9, 10^10, 10^11 vp/dose)as well as 3 vaccine administration schedules (1 and 15 days; 1 and 29 days; 1, 15, and 29 days); 2 of 3 schedules will include an intramuscular (IM) AVA booster immunization, 1 schedule will include 3 vaccine administrations of Ad4-PA or Ad4-PA-GPI (glycosylphosphatidylinositol) alone, and 1 schedule will include 3 vaccine administrations of AVA alone.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Able to understand the study and give written informed consent.
  • Healthy men or women aged 18-40 years old,
  • BMI between 18 to 36 kg/m2
  • Women of child bearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to vaccination on all vaccination days; they must also be willing to use adequate birth control for the duration of the study and have additional pregnancy tests if indicated.
  • Intact upper arms with sufficient muscular tissue in the deltoid region for IM vaccine administration.
  • Subject must be available for the study duration
  • Subject must avoid strenuous exercise for at least 72 hours prior to each study vaccine administration.

Exclusion Criteria:

  • Subject is a healthcare worker who has direct contact with patients or has an household contact (HHC) who is immunodeficient or HIV-positive, pregnant, has an unstable medical condition, or is under the age of 18.
  • Subject is a childcare worker or a parent who has direct contact with children 5 years old and younger.
  • Subject directly prepares food in the food industry.
  • Pregnant or breastfeeding throughout the duration of the study until the final visit
  • Military service between 1971 and 1999, or after 2012 when Ad4 vaccine was/is routinely given
  • Employment in an industry involved in contact with ruminant animals, veterinary sciences, or other potential exposure to B. anthracis
  • Received previous Ad4 vaccination or experimental Ad4 vector vaccines
  • Received previous anthrax vaccine
  • Received or plans to receive any other approved or investigational vaccines from 30 days prior to the first study vaccination until 30 days after the final study vaccination for live attenuated vaccines and from 15 days prior to the first study vaccination until 15 days after the final study vaccination for inactivated vaccines
  • HIV or Hepatitis B or C positive
  • Immunodeficient or has an unstable medical condition including psychiatric conditions
  • Active or past history of acute or chronic gastrointestinal conditions
  • Active or past history of cancer except basal cell carcinoma
  • Recipient of bone marrow or solid organ transplant
  • Received or plans to receive systemic antiviral medication, within 30 days prior to the first study vaccination
  • Known allergy to any component of the study vaccine
  • Known allergy to, or known medical condition that precludes use of any systemic antiviral medication
  • Received or plans to receive medications indicated for decreasing acidity of stomach including:
  • Proton pump inhibitors or antacids or histamine 2-receptor antagonists
  • Received or plans to receive immunoglobulin or other blood products within 60 days prior to the first study vaccination
  • Received or plans to receive other investigational drugs within 30 days prior to the first study vaccination
  • Received or plans to receive systemic immunosuppressive therapy, radiation therapy, or inhaled steroids within 30 days prior to the first study vaccination
  • Asthmatic or requires asthmatic medications on a daily basis
  • Use of systemic chemotherapy within 5 years prior to study
  • Body temperature >38.1°C or acute illness within 3 days prior to vaccination
  • History of excessive alcohol consumption, drug abuse, or significant psychiatric illness
  • History of Guillain-Barré Syndrome
  • Blood donation within 2 months prior to first study vaccination
  • Expected to be noncompliant with study visits or plans to move away or be living with different HHCs during the next 8 months
  • Drinks more than 1200 mL of tea/coffee/cocoa/cola or other caffeinated beverage per day.
  • Any condition or finding that in the view of the primary investigator would impede full study participation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01979406

Locations
United States, Kansas
The Center for Pharmaceutical Research
Kansas City, Kansas, United States, 64114
United States, Maryland
Walter Reed Army Institute for Research
Silver Spring, Maryland, United States, 20910
United States, Missouri
St. Louis University
St. Louis, Missouri, United States, 63104
United States, South Carolina
Coastal Carolina Research Center
Mt. Pleasant, South Carolina, United States, 29464
Sponsors and Collaborators
PaxVax, Inc.
Investigators
Principal Investigator: Marc Gurwith, MD PaxVax, Inc.
Study Director: Jakub Simon, MD PaxVax, Inc.
Principal Investigator: Mo Elsafy, MD, MSc National Institutes of Health (NIH)
  More Information

No publications provided

Responsible Party: PaxVax, Inc.
ClinicalTrials.gov Identifier: NCT01979406     History of Changes
Other Study ID Numbers: PXVX-PA-100-001
Study First Received: October 16, 2013
Last Updated: July 25, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by PaxVax, Inc.:
Anthrax vaccine

Additional relevant MeSH terms:
Anthrax
Bacillaceae Infections
Gram-Positive Bacterial Infections
Bacterial Infections

ClinicalTrials.gov processed this record on September 18, 2014